ArticlePloS one2025
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe term metabolic dysfunction-associated steatotic liver disease (MASLD) reflects the key role of cardiometabolic dysfunction in steatotic liver disease. We aim to assess the association between cardiometabolic dysfunction burden and mortality outcomes in MASLD.
methodsParticipants with MASLD were selected from the National Health and Nutrition Examination Survey (NHANES) database between 1999 and 2018. The mortality outcomes of participants with different numbers of cardiometabolic risk factors were compared by using Kaplan-Meier curves and Cox regression analysis.
resultsThis study included 9,017 participants with MASLD (4,613 men and 4,404 women, median age 49.0). With a median 115-month follow-up, 1,447 all-cause deaths and 407 cardiovascular-specific deaths were observed. Multivariate regression analysis showed that participants with five cardiometabolic risk factors had significantly increased all-cause mortality risk compared to those with one risk factor (adjusted hazard ratio [aHR] = 3.57, 95% confidence interval [CI]: 2.04-6.24, P < 0.001). Similarly, the cardiovascular mortality risk was markedly higher for participants with five risk factors (aHR = 7.72, 95% CI: 1.89-31.53, P = 0.004). Among participants with the same number of cardiometabolic risk factors, those with blood glucose or blood pressure abnormalities showed the lowest survival rates than other subgroups. Besides, participants with younger ages were more vulnerable to the harmful prognostic effects of cardiometabolic dysfunction burden on the mortality risks.
conclusionsThe MASLD population with high cardiometabolic dysfunction burdens exhibits increased mortality risk. Assessing cardiometabolic dysfunction, particularly abnormalities in blood glucose and blood pressure, is crucial for effective management in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.